We help the drugs to help

We offer the safety of our experience

 

Publications

Impacted publications

2021

Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic

Kojanova M, Cetkovaska P, Strosova D, Fialova J, Arenberger P, Dolezal T, Gkalpakiotis S, & The BIOREP Study Group. Dermatology and Therapy (2021)

Smoking in women with chronic vaginal discomfort is not associated with decreased abundance of Lactobacillus spp. but promotes Mobiluncus and Gardnerella spp. overgrowth: secondary analysis of trial data including microbiome analysis

Tužil J, Filková B, Malina J, Kerestes J, Doležal T. Česká gynekologie (2021)

Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex‐specific differences in psoriasis in the Czech Republic

Kojanova M, Fialova J, Cetkovska P,  Dolezal T, Lomicova I, Arenberger P, Gkalpakiotis S, the BIOREP Study Group. Dermatologic therapy (2021)

Cost-Effectiveness Analysis of Parenteral Methotrexate for the Treatment of Crohn’s Disease

Mlcoch T, Decker B, Dolezal T. Applied Health Economics and Health Policy (2021)

2018

Highly Innovative Drug Program in the Czech Republic: Description and Pharmacoeconomic Results— Cost-Effectiveness and Budget Impact Analyses

Ornstova E, Sebestianova M, Mlcoch T, Lamblova K, Dolezal T. Value in Health Regional Issues 16, September (2018): 92-98.

HTA in the Czech Republic: Still Behind

Rogalewicz V, Kubátová I, Donin G, Doležal T, Lamblová K, Bartáková J, Kneppo P World Congress on Medical Physics and Biomedical Engineering 2018 (Vol. 2). Springer Nature Singapore Pte Ltd., 2019. IFMBE Proceedings. vol. 68/2. ISSN 1680-0737. ISBN 978-981-10-9037-0.

Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic

Adenubiova E, Arenberger P, Gkalpakioti P, Arenbergerova M, Jircikova J, Dolezal T, Gkalpakiotis S. J Dermatolog Treat. 2018 Jan 17: 1-4. doi: 10.1080/09546634.2018.1425358. [Epub ahead of print].

 

2017

Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries

Kojanova M, Fialova J, Cetkovska P, Gkalpakiotis S, Jircikova J, Dolezal T, Arenberger P. BIOREP study group. Int J Dermatol. 2017 Apr; 56(4): 428-434.

New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic

Havrdova E, Kobelt G, Berg J, Capsa D, Gannedahl M, Doležal T. European Multiple Sclerosis Platform. Mult Scler. 2017 Aug; 23 (2_suppl): 41-52.

Dietary patterns, cost and compliance with low-protein diet of phenylketonuria and other inherited metabolic diseases

Mlcoch T, Puda R, Jesina P, Lhotakova M, Sterbova S, Dolezal T. Eur J Clin Nutr. 2017 Jun 28. doi: 10.1038/ejcn.2017.102. [Epub ahead of print].

Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis

Mlcoch T, Tuzil J, Sedova L, Stolfa J, Urbanova M, Suchy D, Smrzova A, Jircikova J, Hrnciarova T, Pavelka K and Dolezal T. Patient 2017, Nov 22, doi: https://doi.org/10.1007/s40271-017-0285-1 . [Epub ahead of print].

 

2016

Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study

Mlčoch T, Klimeš J, Jirčíková J, Doležal T, Macek M et al. European Journal of Health Economics (2017): 18: 73-82. Accepted and published online in January 2016.

Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis

Mlčoch T, Šedová L, Štolfa J, Urbanová M, Suchý D, Smržová A, Jirčíková J, Pavelka K, Doležal T. Expert Review of Pharmacoeconomics & Outcomes Research 17(2): 203-211 (2017). Accepted and published online in June 2016.

The Quality of Life following allogeneic Hematopoietic Stem Cell Transplantation – a Multicenter Retrospective Study

Válková V, Jirčíková J, Trnková M, Steinerová K, Keslová P, Lánská M, Kořístek Z, Raida L, Kruntorádová K, Doležal T, Benešová K, Cetkovský P, Trněný M. Neoplasma. 2016 Jul 29; 63(5).

Cost of severe hypoglycaemia in nine European countries

Jakubczyk M, Lipka I, Pawęska J, Niewada M, Rdzanek E, Zaletel J, Ramírez de Arellano A, Doležal T, Chekorova Mitreva B, Nagy B, Petrova G, Šarić T, Yfantopoulos J, Czech M.
J Med Econ. 2016 Oct; 19(10): 973-82.

 

2015

Klinické a ekonomické přínosy nových antidiabetik v České republice

Doležal T, Kruntorádová K. Vnitřní lékařství 2015; 61 (SUppl 3): 3S50-53.

 

2014

Costs of multiple sclerosis - extrapolation of Czech data to Polish patients

Szmurło D, Fundament T, Ziobro M, Kruntorádová K, Doležal T, Głogowski C. Expert Rev Pharmacoecon Outcomes Res. 2014; 14(3): 451-458.

Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis

Kruntoradova K, Klimeš J, Sedova L, Stolfa J, Doležal T, Petříková A. Value in Health Regional Issues. 2014; 4C: 100-106.

Medical and Productivity Costs of Rheumatoid Arthritis in The Czech Republic: Cost-of-Illness Study Based on Disease Severity

Klimeš J, Vocelka M, Šedová L, Doležal T, Mlčoch T, Petříková A, Vlček J. Value in Health Regional Issues 4C (2014): 75-81.

 

2013

The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008

Petříková A, Doležal T, Klimeš J, Vocelka M, Šedová L, Kolář J. Rheumatol Int. 2013; 33: 1813-1819.